17,261 trials
Head and Neck Neoplasms · Cancer of the Head and Neck
Primary: To Measure the Safety and Clinical Effectiveness of the Combination of Carboplatin, Cetuximab and RAD001 in Patients With Advanced (Recurrent or Metastatic) Head and…
Ovarian Cancer
Primary: Percentage of Participants With Disease Progression or Death — 87.8; 80.0 percentage of participants
Ovarian Neoplasms
Primary: PFS Rate at 36 Weeks (After 9 Months) — 15.6; 2.9 percent probability of PFS
Chronic Pain · Low Back Pain
Primary: Health-Related Quality of Life: Averaged Pain Severity — -0.5; 0.4 units on a scale
Oropharyngeal Dysphagia · Oropharyngeal Cancer
Primary: Optimal Respiratory - Swallow Phase — 43; 86; 88.1 percentage of swallows
Colorectal Neoplasms
Primary: pERK and pAKT Levels in Tumor Biopsies on C1D1 and C1D22 Post-administration of the Combination of AZD6244 Hydrogen Sulfate and MK-2206 in Participants With Advanced…
Atypical Hemolytic Uremic Syndrome
Primary: Platelet Count Change From Baseline to 26 Weeks — 65.18 10^9 cells/L — p=<0.0001
Multiple Myeloma
Primary: Overall Response Rate — 87.5 percentage of participants — p=<0.0001
Estrogen Receptor Positive · Male Breast Carcinoma · Progesterone Receptor Positive
Primary: Tumor Response Rate (Complete and Partial) Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) — 1 participants
Infertility, Female
Primary: Embryo Implantation and Clinical Pregnancy Rates — 32; 33 Gestational sacs — p=0.72
Ulcerative Colitis · Inflammatory Bowel Disease
Primary: Number of Participants With Improvement of Signs and Symptoms of UC at 12 Weeks — 23; 12 participants — p=.005
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Overall Response Rate — .083 proportion of participants
Leiomyosarcoma · Uterine Neoplasm
Primary: Two-year Progression-free Survival Among Women Treated With This Adjuvant Regimen for High Risk Uterine LMS — 78 percentage of participants — p=0.15
Scalp Psoriasis
Primary: Percentage of Subjects With Adverse Drug Reactions (ADRs) — 6.4 percent subjects
Atypical Hemolytic Uremic Syndrome
Primary: Platelet Count Change From Baseline to 26 Weeks — 65.18 10^9 cells/L — p=<0.0001